Platelet activation in the hypertensive disorders of pregnancy

Sunil Nadar, Gregory Y H Lip

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The hypertensive disorders of pregnancy, including gestational hypertension, pre-eclampsia and eclampsia, continue to be an important cause of maternal morbidity and mortality. Abnormal placentation is considered to be the main instigating factor, which then leads to widespread maternal endothelial activation and dysfunction. This endothelial perturbation leads to the release of many substances into the circulation, many of which result in platelet activation. For example, there is an imbalance between the levels of prostacyclin (a vasodilator and platelet inhibitor) and thromboxane (a platelet activator and vasoconstrictor), which then results in the maintenance of high blood pressure and complications. It is also likely that platelets play an important part in the pathogenesis of hypertension in pregnancy. The use of antiplatelet drugs has been shown to be effective in reducing the incidence of gestational hypertension in women at high risk and in preventing the complications associated with it. In addition, some antihypertensive agents are effective in reversing platelet activation in essential hypertension and, therefore, their use in pregnancy-induced hypertension may be beneficial in more ways than simply blood pressure reduction. 2004

Original languageEnglish
Pages (from-to)523-529
Number of pages7
JournalExpert Opinion on Investigational Drugs
Volume13
Issue number5
DOIs
Publication statusPublished - May 2004

Fingerprint

Pregnancy Induced Hypertension
Platelet Activation
Platelet Aggregation Inhibitors
Pregnancy
Blood Platelets
Hypertension
Placentation
Eclampsia
Maternal Mortality
Thromboxanes
Vasoconstrictor Agents
Epoprostenol
Pre-Eclampsia
Vasodilator Agents
Antihypertensive Agents
Mothers
Blood Pressure
Morbidity
Incidence

Keywords

  • Platelet activation
  • Platelets
  • Pregnancy-induced hypertension

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Platelet activation in the hypertensive disorders of pregnancy. / Nadar, Sunil; Lip, Gregory Y H.

In: Expert Opinion on Investigational Drugs, Vol. 13, No. 5, 05.2004, p. 523-529.

Research output: Contribution to journalArticle

@article{d8c6acbf61bf44239f3bdcbca42138e4,
title = "Platelet activation in the hypertensive disorders of pregnancy",
abstract = "The hypertensive disorders of pregnancy, including gestational hypertension, pre-eclampsia and eclampsia, continue to be an important cause of maternal morbidity and mortality. Abnormal placentation is considered to be the main instigating factor, which then leads to widespread maternal endothelial activation and dysfunction. This endothelial perturbation leads to the release of many substances into the circulation, many of which result in platelet activation. For example, there is an imbalance between the levels of prostacyclin (a vasodilator and platelet inhibitor) and thromboxane (a platelet activator and vasoconstrictor), which then results in the maintenance of high blood pressure and complications. It is also likely that platelets play an important part in the pathogenesis of hypertension in pregnancy. The use of antiplatelet drugs has been shown to be effective in reducing the incidence of gestational hypertension in women at high risk and in preventing the complications associated with it. In addition, some antihypertensive agents are effective in reversing platelet activation in essential hypertension and, therefore, their use in pregnancy-induced hypertension may be beneficial in more ways than simply blood pressure reduction. 2004",
keywords = "Platelet activation, Platelets, Pregnancy-induced hypertension",
author = "Sunil Nadar and Lip, {Gregory Y H}",
year = "2004",
month = "5",
doi = "10.1517/13543784.13.5.523",
language = "English",
volume = "13",
pages = "523--529",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Platelet activation in the hypertensive disorders of pregnancy

AU - Nadar, Sunil

AU - Lip, Gregory Y H

PY - 2004/5

Y1 - 2004/5

N2 - The hypertensive disorders of pregnancy, including gestational hypertension, pre-eclampsia and eclampsia, continue to be an important cause of maternal morbidity and mortality. Abnormal placentation is considered to be the main instigating factor, which then leads to widespread maternal endothelial activation and dysfunction. This endothelial perturbation leads to the release of many substances into the circulation, many of which result in platelet activation. For example, there is an imbalance between the levels of prostacyclin (a vasodilator and platelet inhibitor) and thromboxane (a platelet activator and vasoconstrictor), which then results in the maintenance of high blood pressure and complications. It is also likely that platelets play an important part in the pathogenesis of hypertension in pregnancy. The use of antiplatelet drugs has been shown to be effective in reducing the incidence of gestational hypertension in women at high risk and in preventing the complications associated with it. In addition, some antihypertensive agents are effective in reversing platelet activation in essential hypertension and, therefore, their use in pregnancy-induced hypertension may be beneficial in more ways than simply blood pressure reduction. 2004

AB - The hypertensive disorders of pregnancy, including gestational hypertension, pre-eclampsia and eclampsia, continue to be an important cause of maternal morbidity and mortality. Abnormal placentation is considered to be the main instigating factor, which then leads to widespread maternal endothelial activation and dysfunction. This endothelial perturbation leads to the release of many substances into the circulation, many of which result in platelet activation. For example, there is an imbalance between the levels of prostacyclin (a vasodilator and platelet inhibitor) and thromboxane (a platelet activator and vasoconstrictor), which then results in the maintenance of high blood pressure and complications. It is also likely that platelets play an important part in the pathogenesis of hypertension in pregnancy. The use of antiplatelet drugs has been shown to be effective in reducing the incidence of gestational hypertension in women at high risk and in preventing the complications associated with it. In addition, some antihypertensive agents are effective in reversing platelet activation in essential hypertension and, therefore, their use in pregnancy-induced hypertension may be beneficial in more ways than simply blood pressure reduction. 2004

KW - Platelet activation

KW - Platelets

KW - Pregnancy-induced hypertension

UR - http://www.scopus.com/inward/record.url?scp=2642525995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642525995&partnerID=8YFLogxK

U2 - 10.1517/13543784.13.5.523

DO - 10.1517/13543784.13.5.523

M3 - Article

C2 - 15155127

AN - SCOPUS:2642525995

VL - 13

SP - 523

EP - 529

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 5

ER -